Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pedro Diaz

Cardiovascular Disease Hialeah, FL Medical Doctor

NPI 1578532800 CMS profile 664534

2387 W 68Th St, Suite 503, Hialeah, FL 33016

Open in the dashboard

General payments

$78,080

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pedro Diaz of Hialeah, FL is reported in the CMS Open Payments database as having received $78,080 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $917 35
2024 General $1,116 48
2023 General $902 16
2022 General $5,745 42
2021 General $52,329 77
2020 General $14,108 35
2019 General $2,963 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pedro Diaz
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Pedro Diaz were reported at $917. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Pedro Diaz Cardiovascular Disease median Middle half National median
2019 $2,963 $450 $127–$1,392 $163
2020 $14,108 $242 $77–$751 $114
2021 $52,329 $335 $101–$1,037 $132
2022 $5,745 $395 $121–$1,211 $149
2023 $902 $443 $136–$1,283 $160
2024 $1,116 $450 $136–$1,323 $164
2025 $917 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Esperion Therapeutics, Inc. $66,898 76 payments
  2. Biotronik Inc. $4,169 38 payments
  3. Abbott Laboratories $1,268 11 payments
  4. Novartis Pharmaceuticals Corporation $1,136 56 payments
  5. Pfizer Inc. $654 26 payments
  6. E.R. Squibb & Sons, L.L.C. $481 18 payments
  7. Atricure, Inc. $411 3 payments
  8. Sanofi-Aventis U.S. LLC $351 9 payments
  9. Medtronic, Inc. $346 3 payments
  10. Surmodics, Inc. $344 4 payments
  11. Other $2,023 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $62,700 32 payments
  2. Food and Beverage $15,233 281 payments
  3. Education $148 3 payments
Products named General payments · program years 2019–2025
  1. NEXLETOL $66,898 76 payments
  2. NEXLIZET $66,619 61 payments
  3. BioMonitor $2,094 20 payments
  4. Solia $1,048 10 payments
  5. Rivacor $919 9 payments
  6. Edora $919 9 payments
  7. Acticor $919 9 payments
  8. ELIQUIS $630 25 payments
  9. ENTRESTO $608 19 payments
  10. Acticor 7 VR-T DX $527 5 payments
  11. Other $8,609 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

14,735

Median for Cardiology: 2,533

Drug cost

$2,016,022

Median for Cardiology: $485,213

Branded share of claims

24.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 953 $858,725
Vyndamax Tafamidis Brand 13 $295,630
Entresto Sacubitril/Valsartan Brand 236 $257,421
Xarelto Rivaroxaban Brand 86 $78,878
Farxiga Dapagliflozin Propanediol Brand 76 $68,839
Ozempic Semaglutide Brand 48 $50,775
Mounjaro Tirzepatide Brand 28 $32,600
Brilinta Ticagrelor Brand 44 $27,271
Tradjenta Linagliptin Brand 29 $22,836
Vascepa Icosapent Ethyl Brand 31 $20,177

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$251,583

Of which drugs: $754

Medicare patients

234

Average age 79

Services billed

1,537

144 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Diabetes 57%
Arthritis 51%
Chronic kidney disease 37%
Depression 34%
Atrial fibrillation 29%
Heart failure 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 63 128 $748

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $330
$330 236 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $69
  • PFIZER INC. $19
$88 953 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $52
$52 — —
Repatha
  • Amgen Inc. $48
$48 17 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record